346 related articles for article (PubMed ID: 28607086)
1. Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease.
Chen JL; Walton KL; Hagg A; Colgan TD; Johnson K; Qian H; Gregorevic P; Harrison CA
Proc Natl Acad Sci U S A; 2017 Jun; 114(26):E5266-E5275. PubMed ID: 28607086
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
3. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Han HQ; Zhou X; Mitch WE; Goldberg AL
Int J Biochem Cell Biol; 2013 Oct; 45(10):2333-47. PubMed ID: 23721881
[TBL] [Abstract][Full Text] [Related]
4. Development of novel activin-targeted therapeutics.
Chen JL; Walton KL; Al-Musawi SL; Kelly EK; Qian H; La M; Lu L; Lovrecz G; Ziemann M; Lazarus R; El-Osta A; Gregorevic P; Harrison CA
Mol Ther; 2015 Mar; 23(3):434-44. PubMed ID: 25399825
[TBL] [Abstract][Full Text] [Related]
5. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.
Souza TA; Chen X; Guo Y; Sava P; Zhang J; Hill JJ; Yaworsky PJ; Qiu Y
Mol Endocrinol; 2008 Dec; 22(12):2689-702. PubMed ID: 18927237
[TBL] [Abstract][Full Text] [Related]
6. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
7. TGFβ and BMP signaling in skeletal muscle: potential significance for muscle-related disease.
Sartori R; Gregorevic P; Sandri M
Trends Endocrinol Metab; 2014 Sep; 25(9):464-71. PubMed ID: 25042839
[TBL] [Abstract][Full Text] [Related]
8. TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass.
Hagg A; Kharoud S; Goodchild G; Goodman CA; Chen JL; Thomson RE; Qian H; Gregorevic P; Harrison CA; Walton KL
Front Physiol; 2020; 11():560225. PubMed ID: 33250771
[TBL] [Abstract][Full Text] [Related]
9. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass.
Winbanks CE; Chen JL; Qian H; Liu Y; Bernardo BC; Beyer C; Watt KI; Thomson RE; Connor T; Turner BJ; McMullen JR; Larsson L; McGee SL; Harrison CA; Gregorevic P
J Cell Biol; 2013 Oct; 203(2):345-57. PubMed ID: 24145169
[TBL] [Abstract][Full Text] [Related]
10. Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.
Olsen OE; Hella H; Elsaadi S; Jacobi C; Martinez-Hackert E; Holien T
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32235336
[TBL] [Abstract][Full Text] [Related]
11. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice.
Qiao C; Li J; Jiang J; Zhu X; Wang B; Li J; Xiao X
Hum Gene Ther; 2008 Mar; 19(3):241-54. PubMed ID: 18288893
[TBL] [Abstract][Full Text] [Related]
12. Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle.
Smith IJ; Aversa Z; Alamdari N; Petkova V; Hasselgren PO
J Cell Biochem; 2010 Nov; 111(4):1059-73. PubMed ID: 20677217
[TBL] [Abstract][Full Text] [Related]
13. Activin A more prominently regulates muscle mass in primates than does GDF8.
Latres E; Mastaitis J; Fury W; Miloscio L; Trejos J; Pangilinan J; Okamoto H; Cavino K; Na E; Papatheodorou A; Willer T; Bai Y; Hae Kim J; Rafique A; Jaspers S; Stitt T; Murphy AJ; Yancopoulos GD; Gromada J
Nat Commun; 2017 Apr; 8():15153. PubMed ID: 28452368
[TBL] [Abstract][Full Text] [Related]
14. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders.
Tsuchida K
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Jun; 4(2):157-66. PubMed ID: 15180456
[TBL] [Abstract][Full Text] [Related]
15. A road map toward defining the role of Smad signaling in hematopoietic stem cells.
Utsugisawa T; Moody JL; Aspling M; Nilsson E; Carlsson L; Karlsson S
Stem Cells; 2006 Apr; 24(4):1128-36. PubMed ID: 16357343
[TBL] [Abstract][Full Text] [Related]
16. Activin A/bone morphogenetic protein (BMP) chimeras exhibit BMP-like activity and antagonize activin and myostatin.
Korupolu RV; Muenster U; Read JD; Vale W; Fischer WH
J Biol Chem; 2008 Feb; 283(7):3782-90. PubMed ID: 18056265
[TBL] [Abstract][Full Text] [Related]
17. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.
Glass DJ
Curr Top Microbiol Immunol; 2010; 346():267-78. PubMed ID: 20593312
[TBL] [Abstract][Full Text] [Related]
18. Regulation of muscle growth by multiple ligands signaling through activin type II receptors.
Lee SJ; Reed LA; Davies MV; Girgenrath S; Goad ME; Tomkinson KN; Wright JF; Barker C; Ehrmantraut G; Holmstrom J; Trowell B; Gertz B; Jiang MS; Sebald SM; Matzuk M; Li E; Liang LF; Quattlebaum E; Stotish RL; Wolfman NM
Proc Natl Acad Sci U S A; 2005 Dec; 102(50):18117-22. PubMed ID: 16330774
[TBL] [Abstract][Full Text] [Related]
19. Bone and morphogenetic protein signalling and muscle mass.
Sartori R; Sandri M
Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):215-20. PubMed ID: 25807347
[TBL] [Abstract][Full Text] [Related]
20. Myostatin: a modulator of skeletal-muscle stem cells.
Walsh FS; Celeste AJ
Biochem Soc Trans; 2005 Dec; 33(Pt 6):1513-7. PubMed ID: 16246158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
